Top 5 Drug Type | Count |
---|---|
Small molecule drug | 91 |
Unknown | 17 |
Monoclonal antibody | 12 |
Bispecific antibody | 8 |
Oncolytic virus | 4 |
Target |
Mechanism IL-36R inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date01 Sep 2022 |
Target |
Mechanism DPP-4 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Jan 2020 |
Target |
Mechanism IL-23p19 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date26 Mar 2019 |
Start Date06 Aug 2024 |
Sponsor / Collaborator |
Start Date27 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Nintedanib esylate ( CSF-1R x FGFRs x FLT3 x PDGFR x VEGFR ) | Idiopathic Pulmonary Fibrosis More | Approved |
Nevirapine ( RT ) | HIV Infections More | Approved |
Vitis vinifera leaf extract | Varicose Veins More | Approved |
Spesolimab ( IL-36R ) | Generalized Pustular Psoriasis More | Approved |
Telmisartan/Amlodipine Besylate/Hydrochlorothiazide ( AT1R x NCC x VDCCs ) | Hypertension More | Approved |